SCHEMBL5740434

SCHEMBL5740434

CC[N]c1ccc(Cl)cc1.[NH]c1ccc2ccccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.43
CYP1A2 P05177 2/20 0.36
HTT P42858 2/20 0.34
MAPT P10636 2/20 0.34
LMNA P02545 1/20 0.34
MEN1 O00255 6/20 0.33
KMT2A Q03164 6/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
TDP1 Q9NUW8 2/20 0.33
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33
HTR3A P46098 1/20 0.33
HTR3D Q70Z44 1/20 0.33
HTR3C Q8WXA8 1/20 0.33
ALDH1A1 P00352 2/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
MPI P34949 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL919684 0.76 HTR3E (0.48) CYP2A6CYP1A2MEN1KMT2ANPC1
SCHEMBL1735291 0.76 NOS3 (0.44) CYP2A6HTTMAPTLMNATDP1
SCHEMBL130318 0.72 CYP2A6 (0.48) CYP2A6CYP1A2TDP1ALDH1A1CYP3A4
SCHEMBL2013278 0.66 ALDH1A1 (0.50) CYP2A6CYP1A2MAPTTDP1ALDH1A1
SCHEMBL8873844 0.63 CYP2A6 (1.00) CYP2A6CYP1A2HTTMAPTLMNA
SCHEMBL29843547 0.63 CYP2A6 (1.00) CYP2A6CYP1A2HTTMAPTLMNA
SCHEMBL152521 0.63 CYP2A6 (1.00) CYP2A6CYP1A2HTTMAPTLMNA
SCHEMBL53706 0.63
SCHEMBL30071035 0.63 CYP2A6 (1.00) CYP2A6CYP1A2HTTMAPTLMNA
Naphthalene SCHEMBL22408860 0.63 CYP2A6 (0.67) CYP2A6CYP1A2MAPTLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1412328-B1 DOLASTATIN 10 DERIVATIVES HOFFMANN LA ROCHE (CH) 2006-10-04 EP claimed
US-20030055002-A1 Dolastatin 10 derivatives HOFFMANN-LA ROCHE INC. 2003-03-20 US claimed
EP-1412328-B1 DOLASTATIN 10 DERIVATIVES HOFFMANN LA ROCHE (CH) 2006-10-04 EP disclosed
EP-1412328-A1 DOLASTATIN 10 DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2004-04-28 EP disclosed
US-20030055002-A1 Dolastatin 10 derivatives HOFFMANN-LA ROCHE INC. 2003-03-20 US disclosed
WO-2003008378-A1 DOLASTATIN 10 DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055002-A1 Dolastatin 10 derivatives DAD1, DDOST, NPC1 CYP2A6 2461/4885CYP1A2 2980/4885HTT 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.